董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Justin J. File | 男 | Chief Executive Officer,Chief Financial Officer,Director and Secretary | 56 | 157.72万美元 | 27.72 | 2026-02-12 |
| James Flynn | 男 | Independent Director | 46 | 25.34万美元 | 21.64 | 2026-02-12 |
| Joshua Riezman | 男 | Director | 43 | 18.11万美元 | 6.25 | 2026-02-12 |
| Charles B. Lee | 男 | Director | 49 | 未披露 | 29.24 | 2026-02-12 |
| Frederick W. Driscoll | 男 | Independent Director and Chair of the Board | 75 | 29.91万美元 | 10.19 | 2026-02-12 |
| Nicholas R. Glover | 男 | Independent Director | 57 | 26.93万美元 | 10.04 | 2026-02-12 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Justin J. File | 男 | Chief Executive Officer,Chief Financial Officer,Director and Secretary | 56 | 157.72万美元 | 27.72 | 2026-02-12 |
董事简历
中英对照 | 中文 | 英文- Justin J. File
-
JustinJ.File自2015年7月起担任私人Evofem&；8217；S首席财务官，自2018年1月起担任我们的首席财务官。最近，他为加州圣地亚哥（San Diego）的各种生物技术公司提供执行财务和会计监督服务，协助他们的首次公开发行过程，并帮助建立和改善他们作为上市实体的会计和财务运营。在此之前，File先生是Sequenom，Inc.公司的高级董事兼财务总监，该公司是一家为妇女保健市场开发分子诊断检测服务并将其商业化的诊断公司。在此期间，他担任其诊断子公司的财务主管，并协助筹集超过4亿美元的合并股本和可转换票据发行。他还在两年的时间里协助商业推出了四种诊断测试，其中包括Sequenom&8217；s革命性的唐氏综合征无创产前测试。职业生涯早期，他曾从事公共会计约10年，主要任职Arthur Andersen LLP，在那里他曾与多种客户合作，协助认证和定期报告要求、公开发行和收购。他毕业于Central Washington University，获得会计和国际商业理学学士学位，是一名不活跃的注册会计师。
Justin J. File was appointed Chief Executive Officer and member of the Board on November 14, 2025. Prior to that, he was appointed Acting Chief Executive Officer on Augt 1, 2024, Chief Financial Officer and Secretary in Augt 2023. Mr. File has over 30 years of experience in accounting and finance, working in both public and private companies. He has a diverse range of experience, having worked in vario indtries, including the life sciences indtry for the past 17 years. From 2015 to 2023, Mr. File was the Chief Financial Officer of Evofem Biosciences, Inc., a women's health company that developed and commercialized Phexxi, a nonhormonal contraceptive for women. While at Evofem, he helped bring the company public through a reverse merger and was responsible for overseeing corporate finance and accounting, information technology and investor relations. Previoly, Mr. File provided executive financial and accounting oversight consulting services to biotechnology companies and before that led accounting operations and reporting at Sequenom, Inc., a molecular diagnostic company. He additionally served as Treasurer of Sequenom's diagnostic subsidiary. Before working in the life sciences indtry, Mr. File worked for approximately ten years in public accounting, primarily with Arthur Andersen LLP. Mr. File graduated from Central Washington University with a Bachelor of Science in Accounting and Biness Administration. He is a Certified Public Accountant (inactive). - JustinJ.File自2015年7月起担任私人Evofem&；8217；S首席财务官，自2018年1月起担任我们的首席财务官。最近，他为加州圣地亚哥（San Diego）的各种生物技术公司提供执行财务和会计监督服务，协助他们的首次公开发行过程，并帮助建立和改善他们作为上市实体的会计和财务运营。在此之前，File先生是Sequenom，Inc.公司的高级董事兼财务总监，该公司是一家为妇女保健市场开发分子诊断检测服务并将其商业化的诊断公司。在此期间，他担任其诊断子公司的财务主管，并协助筹集超过4亿美元的合并股本和可转换票据发行。他还在两年的时间里协助商业推出了四种诊断测试，其中包括Sequenom&8217；s革命性的唐氏综合征无创产前测试。职业生涯早期，他曾从事公共会计约10年，主要任职Arthur Andersen LLP，在那里他曾与多种客户合作，协助认证和定期报告要求、公开发行和收购。他毕业于Central Washington University，获得会计和国际商业理学学士学位，是一名不活跃的注册会计师。
- Justin J. File was appointed Chief Executive Officer and member of the Board on November 14, 2025. Prior to that, he was appointed Acting Chief Executive Officer on Augt 1, 2024, Chief Financial Officer and Secretary in Augt 2023. Mr. File has over 30 years of experience in accounting and finance, working in both public and private companies. He has a diverse range of experience, having worked in vario indtries, including the life sciences indtry for the past 17 years. From 2015 to 2023, Mr. File was the Chief Financial Officer of Evofem Biosciences, Inc., a women's health company that developed and commercialized Phexxi, a nonhormonal contraceptive for women. While at Evofem, he helped bring the company public through a reverse merger and was responsible for overseeing corporate finance and accounting, information technology and investor relations. Previoly, Mr. File provided executive financial and accounting oversight consulting services to biotechnology companies and before that led accounting operations and reporting at Sequenom, Inc., a molecular diagnostic company. He additionally served as Treasurer of Sequenom's diagnostic subsidiary. Before working in the life sciences indtry, Mr. File worked for approximately ten years in public accounting, primarily with Arthur Andersen LLP. Mr. File graduated from Central Washington University with a Bachelor of Science in Accounting and Biness Administration. He is a Certified Public Accountant (inactive).
- James Flynn
-
詹姆斯·弗林如果当选，将成为董事会成员，自2022年年会起生效。Flynn先生目前是Nerium Capital LLC的管理成员和投资组合经理，Nerium Capital LLC是他于2021年创立的投资顾问。Nerium Capital LLC是Nerium Partners LP的普通合伙人，这是一家专注于医疗保健的投资合伙企业。Flynn先生目前还担任Axiom Health的董事会成员，该公司自2022年起为医疗保健行业提供软件和大数据解决方案，并自2020年起担任该公司的顾问。2017年至2018年，弗林先生在一家投资公司Aptigon Capital a Citadel Company担任治疗分析师。在此之前，Flynn先生于2003年至2017年在投资公司Amici Capital，LLC担任过多个职务，包括医疗保健投资组合经理（2008年至2017年）。从2002年到2003年，Flynn先生在投资公司Putnam Investments的信贷研究/高收益小组工作。Flynn先生在麻省理工学院（MIT）获得管理科学学士学位，主修金融学，辅修经济科学。Flynn先生是特许金融分析师（CFA）的持证人。
James Flynn has been a director of Lite Strategy since October 2023. Mr. Flynn is currently a Managing Member and Portfolio Manager of Nerium Capital LLC, an investment adviser he founded in 2021. Mr. Flynn also currently serves on the board of directors of Synlogic, Inc. (NASDAQ: SYBX), a biopharmaceutical company with a foc on rare metabolic disorders and RiceBran Technologies, an innovative specialty ingredients company, both since 2024. Previoly, Mr. Flynn served on the board of directors of ARCA Biopharma (NASDAQ: ABIO), a clinical stage biopharmaceutical company, and Axiom Health, Inc. (Axiom), a provider of software and big data solutions to the healthcare indtry. He also served as an advisor to Axiom since Augt 2002. Prior to that, Mr. Flynn worked in vario investment management roles at Aptigon Capital (a division of Citadel LLC), Amici Capital, LLC and Putnam Investments LLC. Mr. Flynn earned a S.B. degree in Management Science with a concentration in Finance and a minor in Economic Science from the Massachetts Institute of Technology. Mr. Flynn is a Chartered Financial Analyst (CFA) charterholder. - 詹姆斯·弗林如果当选，将成为董事会成员，自2022年年会起生效。Flynn先生目前是Nerium Capital LLC的管理成员和投资组合经理，Nerium Capital LLC是他于2021年创立的投资顾问。Nerium Capital LLC是Nerium Partners LP的普通合伙人，这是一家专注于医疗保健的投资合伙企业。Flynn先生目前还担任Axiom Health的董事会成员，该公司自2022年起为医疗保健行业提供软件和大数据解决方案，并自2020年起担任该公司的顾问。2017年至2018年，弗林先生在一家投资公司Aptigon Capital a Citadel Company担任治疗分析师。在此之前，Flynn先生于2003年至2017年在投资公司Amici Capital，LLC担任过多个职务，包括医疗保健投资组合经理（2008年至2017年）。从2002年到2003年，Flynn先生在投资公司Putnam Investments的信贷研究/高收益小组工作。Flynn先生在麻省理工学院（MIT）获得管理科学学士学位，主修金融学，辅修经济科学。Flynn先生是特许金融分析师（CFA）的持证人。
- James Flynn has been a director of Lite Strategy since October 2023. Mr. Flynn is currently a Managing Member and Portfolio Manager of Nerium Capital LLC, an investment adviser he founded in 2021. Mr. Flynn also currently serves on the board of directors of Synlogic, Inc. (NASDAQ: SYBX), a biopharmaceutical company with a foc on rare metabolic disorders and RiceBran Technologies, an innovative specialty ingredients company, both since 2024. Previoly, Mr. Flynn served on the board of directors of ARCA Biopharma (NASDAQ: ABIO), a clinical stage biopharmaceutical company, and Axiom Health, Inc. (Axiom), a provider of software and big data solutions to the healthcare indtry. He also served as an advisor to Axiom since Augt 2002. Prior to that, Mr. Flynn worked in vario investment management roles at Aptigon Capital (a division of Citadel LLC), Amici Capital, LLC and Putnam Investments LLC. Mr. Flynn earned a S.B. degree in Management Science with a concentration in Finance and a minor in Economic Science from the Massachetts Institute of Technology. Mr. Flynn is a Chartered Financial Analyst (CFA) charterholder.
- Joshua Riezman
-
根据与GSR Strategies LLC于2025年7月22日就PIPE签订的附函，Joshua Riezman于2025年8月5日被任命为Lite Strategy的董事。Riezman先生目前担任全球数字资产交易和投资公司GSR Services LLC的首席战略官–兼全球副总法律顾问。他领导美国biness战略和监管举措，同时还监督该公司的法律和合规职能。在加入GSR Services A LLC之前，Riezman先生是助理总法律顾问——全球数字货币金融科技公司Circle的产品和监管法律主管，在那里他领导了产品和监管法律职能，并就复杂的全球金融监管事务提供咨询。在加入Circle之前，他曾在Soci é t é G é n é rale担任董事和法律顾问– Prime Services和Clearing Legal（Americas）主管，previoly曾在德意志银行和Teigland Hunt LLP担任法律职务，在美国和国际衍生品、清算和金融监管方面拥有专长。Riezman先生在福特汉姆大学法学院获得法学博士学位，在那里他担任《环境法评论》的高级文章编辑，并在乔治华盛顿大学获得国际事务学士学位。
Joshua Riezman was appointed as a director of Lite Strategy on August 5, 2025 pursuant to a Side Letter with GSR Strategies LLC (GSR) entered into in connection with the private investment in public equity (PIPE) on July 22, 2025. Mr. Riezman currently serves as Chief Legal and Strategy Officer at GSR, a global digital asset trading and investment firm. He leads biness strategy and regulatory initiatives, while also overseeing the firm's legal and compliance functions. Prior to GSR, Mr. Riezman was Assistant General Counsel – Head of Product and Regulatory Legal at Circle, a global digital currency fintech firm, where he led the product and regulatory legal function and advised on complex global financial regulatory matters. Before Circle, he served as Director and Counsel – Head of Prime Services and Clearing Legal (Americas) at Société Générale and previoly held legal roles at Deutsche Bank and Teigland Hunt LLP, with expertise in trading, clearing and ctody in the securities, commodities and derivatives markets. Mr. Riezman received his J.D. from Fordham University School of Law, where he served as Senior Articles Editor for the Environmental Law Review and earned his B.A. in International Affairs from The George Washington University. - 根据与GSR Strategies LLC于2025年7月22日就PIPE签订的附函，Joshua Riezman于2025年8月5日被任命为Lite Strategy的董事。Riezman先生目前担任全球数字资产交易和投资公司GSR Services LLC的首席战略官–兼全球副总法律顾问。他领导美国biness战略和监管举措，同时还监督该公司的法律和合规职能。在加入GSR Services A LLC之前，Riezman先生是助理总法律顾问——全球数字货币金融科技公司Circle的产品和监管法律主管，在那里他领导了产品和监管法律职能，并就复杂的全球金融监管事务提供咨询。在加入Circle之前，他曾在Soci é t é G é n é rale担任董事和法律顾问– Prime Services和Clearing Legal（Americas）主管，previoly曾在德意志银行和Teigland Hunt LLP担任法律职务，在美国和国际衍生品、清算和金融监管方面拥有专长。Riezman先生在福特汉姆大学法学院获得法学博士学位，在那里他担任《环境法评论》的高级文章编辑，并在乔治华盛顿大学获得国际事务学士学位。
- Joshua Riezman was appointed as a director of Lite Strategy on August 5, 2025 pursuant to a Side Letter with GSR Strategies LLC (GSR) entered into in connection with the private investment in public equity (PIPE) on July 22, 2025. Mr. Riezman currently serves as Chief Legal and Strategy Officer at GSR, a global digital asset trading and investment firm. He leads biness strategy and regulatory initiatives, while also overseeing the firm's legal and compliance functions. Prior to GSR, Mr. Riezman was Assistant General Counsel – Head of Product and Regulatory Legal at Circle, a global digital currency fintech firm, where he led the product and regulatory legal function and advised on complex global financial regulatory matters. Before Circle, he served as Director and Counsel – Head of Prime Services and Clearing Legal (Americas) at Société Générale and previoly held legal roles at Deutsche Bank and Teigland Hunt LLP, with expertise in trading, clearing and ctody in the securities, commodities and derivatives markets. Mr. Riezman received his J.D. from Fordham University School of Law, where he served as Senior Articles Editor for the Environmental Law Review and earned his B.A. in International Affairs from The George Washington University.
- Charles B. Lee
-
Charles B. Lee于2025年7月22日被任命为Lite Strategy的董事。Lee先生目前还担任BTCS，Inc（NASDAQ：BTCS）的董事会成员，该公司自2021年以来一直专注于数字资产和区块链技术。李先生是莱特币的创造者，也是莱特币基金会的董事。李先生于2000年毕业于麻省理工学院，获得电气工程和计算机科学学士和硕士学位。在创建莱特币之前，李先生是谷歌的一名软件工程师。2011年，李先生创建了莱特币，努力改善比特币的高费用、交易时间缓慢和可扩展性问题。Lee NT先生继续在Coinbase工作，在那里他成为了工程总监，之后于2017年离开公司，向FOC全职支持莱特币的发展。
Charles B. Lee was appointed as a director of Lite Strategy on July 22, 2025. Mr. Lee also currently serves on the board of BTCS, Inc (NASDAQ: BTCS), a digital asset and blockchain technology foced company since 2021. Mr. Lee is the creator of Litecoin and a director of the Litecoin Foundation. Mr. Lee attended MIT where he graduated in 2000 with a bachelor's and master's degree in electrical engineering and computer science. Prior to creating Litecoin, Mr. Lee was a Software Engineer at Google. In 2011, Mr. Lee created Litecoin in an effort to improve upon Bitcoin's high fees, slor transaction times and scalability issues. Mr. Lee nt on to work for Coinbase where he became Director of Engineering before leaving the company in 2017 to foc on supporting the development of Litecoin full time. - Charles B. Lee于2025年7月22日被任命为Lite Strategy的董事。Lee先生目前还担任BTCS，Inc（NASDAQ：BTCS）的董事会成员，该公司自2021年以来一直专注于数字资产和区块链技术。李先生是莱特币的创造者，也是莱特币基金会的董事。李先生于2000年毕业于麻省理工学院，获得电气工程和计算机科学学士和硕士学位。在创建莱特币之前，李先生是谷歌的一名软件工程师。2011年，李先生创建了莱特币，努力改善比特币的高费用、交易时间缓慢和可扩展性问题。Lee NT先生继续在Coinbase工作，在那里他成为了工程总监，之后于2017年离开公司，向FOC全职支持莱特币的发展。
- Charles B. Lee was appointed as a director of Lite Strategy on July 22, 2025. Mr. Lee also currently serves on the board of BTCS, Inc (NASDAQ: BTCS), a digital asset and blockchain technology foced company since 2021. Mr. Lee is the creator of Litecoin and a director of the Litecoin Foundation. Mr. Lee attended MIT where he graduated in 2000 with a bachelor's and master's degree in electrical engineering and computer science. Prior to creating Litecoin, Mr. Lee was a Software Engineer at Google. In 2011, Mr. Lee created Litecoin in an effort to improve upon Bitcoin's high fees, slor transaction times and scalability issues. Mr. Lee nt on to work for Coinbase where he became Director of Engineering before leaving the company in 2017 to foc on supporting the development of Litecoin full time.
- Frederick W. Driscoll
-
Frederick W. Driscoll自2018年2月起担任Lite Strategy, Inc.的董事，并于2024年7月22日被任命为董事会主席。他目前担任Cellectar Biosciences， Inc.（临床阶段生物制药公司）和Adipo Therapeutics（私人临床前阶段生物制药公司）的董事会成员。从2022年9月到2023年5月，他担任Invivyd， Inc.的临时首席财务官。从2022年3月至6月，他担任Renovacor， Inc.（领先的后期生物技术公司）的首席财务官。他曾担任Flexion Therapeutics， Inc.（商业阶段生物制药公司）的首席财务官（2013年至2017年），并于2021年6月重新加入，担任首席财务官，直到该公司被出售给Pacira BioScience。在加入Flexion之前，他从2009年到2013年担任Novavax， Inc.的首席财务官。从2008年到2009年，他担任Genelabs Technologies， Inc.的首席执行官；从2007年到2008年，他担任其首席财务官。2000年至2006年，他也是OXiGENE， Inc.的首席执行官。他还担任OXiGENE的董事会主席和审计委员会主席，以及Cynaps Therapeutics， Inc.的审计委员会成员。他持有Bentley大学的会计和金融学士学位。
Frederick W. Driscoll has served as a director of the Company since April 2017. Mr. Driscoll previously served as Interim CFO at Invivyd, Inc., a biopharmaceutical company developing antibody therapies for infectious diseases, a position he held from October 2022 to September 2023. Mr. Driscoll served as CFO of Renovacor, a former biotechnology company that focused on developing gene therapies for genetic heart disease, from March to June in 2022, while the company was in the process of being sold to Rocket Pharmaceuticals. Mr. Driscoll served as Chief Financial Officer at Flexion Therapeutics, a biopharmaceutical company, from 2013 to 2017, spearheading an initial public offering in 2014. Prior to joining Flexion, he was Chief Financial Officer at Novavax, Inc., a publicly traded biopharmaceutical company, from 2009 to 2013. From 2008 to 2009, Mr. Driscoll served as Chief Executive Officer of Genelabs Technologies, Inc., a publicly traded biopharmaceutical and diagnostics company later acquired by GlaxoSmithKline. He previously served as Genelabs' Chief Financial Officer from 2007 to 2008. From 2000 to 2006, Mr. Driscoll served as Chief Executive Officer at OXiGENE, Inc., a biopharmaceutical company. Mr. Driscoll has also served as Chairman of the Board and Audit Committee Chair at OXiGENE and as a member of the Audit Committee for Cynapsus, a specialty central nervous system pharmaceutical company which was sold to Sunovion Pharmaceuticals in 2016. Mr. Driscoll earned a Bachelor's degree in accounting and finance from Bentley University. Mr. Driscoll is a member of the board of directors of Cue Biopharma and Lite Strategy and was a member of the board of directors of ImmunityBio, Inc. until March 2021. - Frederick W. Driscoll自2018年2月起担任Lite Strategy, Inc.的董事，并于2024年7月22日被任命为董事会主席。他目前担任Cellectar Biosciences， Inc.（临床阶段生物制药公司）和Adipo Therapeutics（私人临床前阶段生物制药公司）的董事会成员。从2022年9月到2023年5月，他担任Invivyd， Inc.的临时首席财务官。从2022年3月至6月，他担任Renovacor， Inc.（领先的后期生物技术公司）的首席财务官。他曾担任Flexion Therapeutics， Inc.（商业阶段生物制药公司）的首席财务官（2013年至2017年），并于2021年6月重新加入，担任首席财务官，直到该公司被出售给Pacira BioScience。在加入Flexion之前，他从2009年到2013年担任Novavax， Inc.的首席财务官。从2008年到2009年，他担任Genelabs Technologies， Inc.的首席执行官；从2007年到2008年，他担任其首席财务官。2000年至2006年，他也是OXiGENE， Inc.的首席执行官。他还担任OXiGENE的董事会主席和审计委员会主席，以及Cynaps Therapeutics， Inc.的审计委员会成员。他持有Bentley大学的会计和金融学士学位。
- Frederick W. Driscoll has served as a director of the Company since April 2017. Mr. Driscoll previously served as Interim CFO at Invivyd, Inc., a biopharmaceutical company developing antibody therapies for infectious diseases, a position he held from October 2022 to September 2023. Mr. Driscoll served as CFO of Renovacor, a former biotechnology company that focused on developing gene therapies for genetic heart disease, from March to June in 2022, while the company was in the process of being sold to Rocket Pharmaceuticals. Mr. Driscoll served as Chief Financial Officer at Flexion Therapeutics, a biopharmaceutical company, from 2013 to 2017, spearheading an initial public offering in 2014. Prior to joining Flexion, he was Chief Financial Officer at Novavax, Inc., a publicly traded biopharmaceutical company, from 2009 to 2013. From 2008 to 2009, Mr. Driscoll served as Chief Executive Officer of Genelabs Technologies, Inc., a publicly traded biopharmaceutical and diagnostics company later acquired by GlaxoSmithKline. He previously served as Genelabs' Chief Financial Officer from 2007 to 2008. From 2000 to 2006, Mr. Driscoll served as Chief Executive Officer at OXiGENE, Inc., a biopharmaceutical company. Mr. Driscoll has also served as Chairman of the Board and Audit Committee Chair at OXiGENE and as a member of the Audit Committee for Cynapsus, a specialty central nervous system pharmaceutical company which was sold to Sunovion Pharmaceuticals in 2016. Mr. Driscoll earned a Bachelor's degree in accounting and finance from Bentley University. Mr. Driscoll is a member of the board of directors of Cue Biopharma and Lite Strategy and was a member of the board of directors of ImmunityBio, Inc. until March 2021.
- Nicholas R. Glover
-
Nicholas R. Glover自2013年6月起担任Lite Strategy, Inc.的董事。他目前是MycRx Holdings Inc.（一家私人持有的药物发现公司）的首席执行官，并担任生物技术行业的顾问。此前，从2014年7月到2020年5月，他担任Sierra Oncology（纳斯达克股票代码：SRRA）的总裁兼首席执行官，这是一家专注于推进癌症患者治疗的靶向治疗的药物开发公司。加入Sierra之前，他曾担任YM Biosciences（肿瘤药物开发公司）的总裁兼首席执行官（从2010年11月到2013年2月被Gilead Sciences收购）。此前，他曾担任Viventia Biotech（一家生物制药公司，参与发现和开发用于治疗癌症的基于单克隆抗体的技术）的总裁兼首席执行官，他在MDS Capital（一家生命科学风险投资公司）担任投资经理后加入该公司。他持有英国East Anglia大学化学荣誉学士学位、加拿大British Columbia大学化学硕士学位和加拿大Simon Fraser大学化学博士学位。
Nicholas R. Glover has been a director of Lite Strategy since June 2013. He is currently Chief Executive Officer of MycRx Holdings Inc., a privately held drug discovery company, and serves as a consultant to the biotech indtry. Previoly, he served as President and Chief Executive Officer of Sierra Oncology (NASDAQ: SRRA), a drug development company foced on advancing targeted therapeutics for the treatment of patients with cancer, from July 2014 through May 2020. Prior to joining Sierra, he served as President and Chief Executive Officer of YM Biosciences, an oncology drug development company, from November 2010 until its acquisition by Gilead Sciences in February 2013. Previoly, Dr. Glover was President and Chief Executive Officer of Viventia Biotech, a biopharmaceutical company involved in the discovery and development of monoclonal antibody based technologies for the treatment of cancer, which he joined after serving as an investment manager for MDS Capital, a life sciences venture capital firm. Dr. Glover holds a B.Sc. (Hons) in Chemistry from the University of East Anglia, U.K., a M.Sc. in Chemistry from the University of British Columbia, Canada and a Ph.D. in Chemistry from Simon Fraser University, Canada. - Nicholas R. Glover自2013年6月起担任Lite Strategy, Inc.的董事。他目前是MycRx Holdings Inc.（一家私人持有的药物发现公司）的首席执行官，并担任生物技术行业的顾问。此前，从2014年7月到2020年5月，他担任Sierra Oncology（纳斯达克股票代码：SRRA）的总裁兼首席执行官，这是一家专注于推进癌症患者治疗的靶向治疗的药物开发公司。加入Sierra之前，他曾担任YM Biosciences（肿瘤药物开发公司）的总裁兼首席执行官（从2010年11月到2013年2月被Gilead Sciences收购）。此前，他曾担任Viventia Biotech（一家生物制药公司，参与发现和开发用于治疗癌症的基于单克隆抗体的技术）的总裁兼首席执行官，他在MDS Capital（一家生命科学风险投资公司）担任投资经理后加入该公司。他持有英国East Anglia大学化学荣誉学士学位、加拿大British Columbia大学化学硕士学位和加拿大Simon Fraser大学化学博士学位。
- Nicholas R. Glover has been a director of Lite Strategy since June 2013. He is currently Chief Executive Officer of MycRx Holdings Inc., a privately held drug discovery company, and serves as a consultant to the biotech indtry. Previoly, he served as President and Chief Executive Officer of Sierra Oncology (NASDAQ: SRRA), a drug development company foced on advancing targeted therapeutics for the treatment of patients with cancer, from July 2014 through May 2020. Prior to joining Sierra, he served as President and Chief Executive Officer of YM Biosciences, an oncology drug development company, from November 2010 until its acquisition by Gilead Sciences in February 2013. Previoly, Dr. Glover was President and Chief Executive Officer of Viventia Biotech, a biopharmaceutical company involved in the discovery and development of monoclonal antibody based technologies for the treatment of cancer, which he joined after serving as an investment manager for MDS Capital, a life sciences venture capital firm. Dr. Glover holds a B.Sc. (Hons) in Chemistry from the University of East Anglia, U.K., a M.Sc. in Chemistry from the University of British Columbia, Canada and a Ph.D. in Chemistry from Simon Fraser University, Canada.
高管简历
中英对照 | 中文 | 英文- Justin J. File
JustinJ.File自2015年7月起担任私人Evofem&；8217；S首席财务官，自2018年1月起担任我们的首席财务官。最近，他为加州圣地亚哥（San Diego）的各种生物技术公司提供执行财务和会计监督服务，协助他们的首次公开发行过程，并帮助建立和改善他们作为上市实体的会计和财务运营。在此之前，File先生是Sequenom，Inc.公司的高级董事兼财务总监，该公司是一家为妇女保健市场开发分子诊断检测服务并将其商业化的诊断公司。在此期间，他担任其诊断子公司的财务主管，并协助筹集超过4亿美元的合并股本和可转换票据发行。他还在两年的时间里协助商业推出了四种诊断测试，其中包括Sequenom&8217；s革命性的唐氏综合征无创产前测试。职业生涯早期，他曾从事公共会计约10年，主要任职Arthur Andersen LLP，在那里他曾与多种客户合作，协助认证和定期报告要求、公开发行和收购。他毕业于Central Washington University，获得会计和国际商业理学学士学位，是一名不活跃的注册会计师。
Justin J. File was appointed Chief Executive Officer and member of the Board on November 14, 2025. Prior to that, he was appointed Acting Chief Executive Officer on Augt 1, 2024, Chief Financial Officer and Secretary in Augt 2023. Mr. File has over 30 years of experience in accounting and finance, working in both public and private companies. He has a diverse range of experience, having worked in vario indtries, including the life sciences indtry for the past 17 years. From 2015 to 2023, Mr. File was the Chief Financial Officer of Evofem Biosciences, Inc., a women's health company that developed and commercialized Phexxi, a nonhormonal contraceptive for women. While at Evofem, he helped bring the company public through a reverse merger and was responsible for overseeing corporate finance and accounting, information technology and investor relations. Previoly, Mr. File provided executive financial and accounting oversight consulting services to biotechnology companies and before that led accounting operations and reporting at Sequenom, Inc., a molecular diagnostic company. He additionally served as Treasurer of Sequenom's diagnostic subsidiary. Before working in the life sciences indtry, Mr. File worked for approximately ten years in public accounting, primarily with Arthur Andersen LLP. Mr. File graduated from Central Washington University with a Bachelor of Science in Accounting and Biness Administration. He is a Certified Public Accountant (inactive).- JustinJ.File自2015年7月起担任私人Evofem&；8217；S首席财务官，自2018年1月起担任我们的首席财务官。最近，他为加州圣地亚哥（San Diego）的各种生物技术公司提供执行财务和会计监督服务，协助他们的首次公开发行过程，并帮助建立和改善他们作为上市实体的会计和财务运营。在此之前，File先生是Sequenom，Inc.公司的高级董事兼财务总监，该公司是一家为妇女保健市场开发分子诊断检测服务并将其商业化的诊断公司。在此期间，他担任其诊断子公司的财务主管，并协助筹集超过4亿美元的合并股本和可转换票据发行。他还在两年的时间里协助商业推出了四种诊断测试，其中包括Sequenom&8217；s革命性的唐氏综合征无创产前测试。职业生涯早期，他曾从事公共会计约10年，主要任职Arthur Andersen LLP，在那里他曾与多种客户合作，协助认证和定期报告要求、公开发行和收购。他毕业于Central Washington University，获得会计和国际商业理学学士学位，是一名不活跃的注册会计师。
- Justin J. File was appointed Chief Executive Officer and member of the Board on November 14, 2025. Prior to that, he was appointed Acting Chief Executive Officer on Augt 1, 2024, Chief Financial Officer and Secretary in Augt 2023. Mr. File has over 30 years of experience in accounting and finance, working in both public and private companies. He has a diverse range of experience, having worked in vario indtries, including the life sciences indtry for the past 17 years. From 2015 to 2023, Mr. File was the Chief Financial Officer of Evofem Biosciences, Inc., a women's health company that developed and commercialized Phexxi, a nonhormonal contraceptive for women. While at Evofem, he helped bring the company public through a reverse merger and was responsible for overseeing corporate finance and accounting, information technology and investor relations. Previoly, Mr. File provided executive financial and accounting oversight consulting services to biotechnology companies and before that led accounting operations and reporting at Sequenom, Inc., a molecular diagnostic company. He additionally served as Treasurer of Sequenom's diagnostic subsidiary. Before working in the life sciences indtry, Mr. File worked for approximately ten years in public accounting, primarily with Arthur Andersen LLP. Mr. File graduated from Central Washington University with a Bachelor of Science in Accounting and Biness Administration. He is a Certified Public Accountant (inactive).